Biotech Values

[DewDiligence]

ELN attractive bait for BIIB following Bapi failure, say some analysts:

http://www.bloomberg.com/news/2012-07-26/alzheimer-s-setback-makes-elan-takeover-bait-to-biogen.html

An acquirer would benefit from Ireland’s low corporate tax rate and Elan’s $3.19 billion in net operating losses at the end of 2011, which could be used to reduce the buyer’s taxes, said Corey Davis, a New York-based analyst for Jefferies.

Maybe.